| Species Reactivity | Human |
| Clone | adimanebart |
| Source/Isotype | Human IgG1(L234A,L235A, K447del), lambda2 |
| Application | / |
| Specificity | Detects MUSK |
| Gene | MUSK |
| Other Names | CMS9, FADS |
| Gene ID | 4593 (Human) |
| Background | Adimanebart is a drug under research. As a MuSK agonist, it was once highly anticipated for the treatment of neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). The registration studies of adimanebart in the field of rare diseases like congenital myasthenic syndrome are still progressing as planned. Its mechanism of improving neuromuscular junction function by activating the MuSK signaling pathway provides important references for the exploration of novel neuroprotective therapies. |
| Storage | Store at 2-8℃ short term (1-2 weeks).Store at ≤ -20℃ long term. Avoid repeated freeze-thaw. |
| Formulation | Supplied as a 0.2 μm filtered solution of PBS, pH7.2-7.4. |
| Endotoxin | < 1 EU/mg, determined by LAL gel clotting assay |
| Species Reactivity | Human |
| Clone | adimanebart |
| Source/Isotype | Human IgG1(L234A,L235A, K447del), lambda2 |
| Application | / |
| Specificity | Detects MUSK |
| Gene | MUSK |
| Other Names | CMS9, FADS |
| Gene ID | 4593 (Human) |
| Background | Adimanebart is a drug under research. As a MuSK agonist, it was once highly anticipated for the treatment of neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). The registration studies of adimanebart in the field of rare diseases like congenital myasthenic syndrome are still progressing as planned. Its mechanism of improving neuromuscular junction function by activating the MuSK signaling pathway provides important references for the exploration of novel neuroprotective therapies. |
| Storage | Store at 2-8℃ short term (1-2 weeks).Store at ≤ -20℃ long term. Avoid repeated freeze-thaw. |
| Formulation | Supplied as a 0.2 μm filtered solution of PBS, pH7.2-7.4. |
| Endotoxin | < 1 EU/mg, determined by LAL gel clotting assay |
